drugset
drugset / Trial / NCT05085106

Safety, Tolerability and Pharmacokinetics of Felbinac Trometamol Eye Drops

NCT05085106 ↗

Phase 1 Unknown 48 enrolled Beijing Tongren Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety and tolerability of felbinac trometamol eye drops of single-dose, multiple-dose, dose escalation in healthy subjects, for providing the basis for the dose setting in the later clinical study.

Timeline

Start
2020-10-21
Primary completion
2021-10-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Felbinac Trometamol Unknown 0.025 % Other
Subject Felbinac Trometamol Unknown 0.05 % Other
Subject Felbinac Trometamol Unknown 0.1 % Other
Subject Felbinac Trometamol Unknown 0.2 % Other
Subject Felbinac Trometamol Unknown 0.3 % Other

Indications

No indication recorded.